DLBCL: Clinical Trials

6 trials for DLBCL, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated. 6 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Terminated 6
Phase 23Terminated 3

Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
TG-1801, Ublituximab - CLL, SLL
Phase 1TerminatedTG Therapeutics, Inc.212021-04-282024-07-31
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
imvotamab - Non-Hodgkin Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2TerminatedIGM Biosciences, Inc.972019-09-302024-07-24
Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy
Entospletinib, Rituximab, Cyclophosphamide - DLBCL
Phase 1 / Phase 2TerminatedThe Lymphoma Academic Research Organisation252017-07-262020-09-02
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
acalabrutinib, vistusertib - DLBCL, Richter Syndrome
Phase 1 / Phase 2TerminatedAcerta Pharma BV252017-06-292021-01-06
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
Birabresib Dose 20 mg - AML Including AML de Novo and AML Secondary to MDS, DLBCL
Phase 1TerminatedMerck Sharp & Dohme LLC92016-05-192022-09-13
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
SGN-CD19B - Non-Hodgkin Lymphoma, DLBCL
Phase 1TerminatedSeagen Inc.442016-02-012018-08-13

Narrower conditions

Lymphoma, Follicular (3)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Lymphoma (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Recurrence (1)

Broader conditions

Hemic and Lymphatic Diseases (3)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Lymphatic Diseases (3)  ·  Lymphoma, B-Cell (3)  ·  Lymphoproliferative Disorders (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Lymphoma (2)  ·  Disease Attributes (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1)  ·  Cyclophosphamide (1)  ·  Doxorubicin (1)  ·  LFB-R603 (1)  ·  OTX015 (1)  ·  Prednisone (1)  ·  Rituximab (1)  ·  SGN-CD19B (1)  ·  Vincristine (1)  ·  acalabrutinib (1)  ·  ublituximab (1)  ·  vistusertib (1)

Sponsors

Acerta Pharma BV (1)  ·  IGM Biosciences, Inc. (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Seagen Inc. (1)  ·  TG Therapeutics, Inc. (1)  ·  The Lymphoma Academic Research Organisation (1)

Countries

United States (4)  ·  France (2)  ·  Australia (1)  ·  Belgium (1)  ·  Czechia (1)  ·  Italy (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Emmanuelle Tchernonog (1)  ·  Gilles Salles (1)  ·  Juan Pinelli, PA-C, MMSc (1)  ·  Julien Depaus (1)

Results publications

PMID 28903943, PMID 34269152, PMID 35538512

NIH funding

2015 (1)